Abstract
Propofol is a commonly used intravenous anesthetic agent with antioxidant properties. However, the effect of propofol on oxidative stress index (OSI) and lipid peroxidation in Parkinson’s disease is still unknown. The present study aimed to evaluate the effect of propofol on OSI and malondialdehyde (MDA) level in the selected brain regions of the rats with Parkinson’s disease (PD). 32 male Wistar rats were divided into four groups: I- control group, II- group with PD, III-control group with propofol, IV-PD group with propofol. 60mg/kg of propofol was given to the 8-weeks-old rats intraperitoneally, and the selected parts of the rats’ brains (frontal cortex, striatum, thalamus and hippocampus) were isolated after decapitation. The concentration of MDA, which is a marker of lipid peroxidation, and OSI were measured. In group IV compared to group II, was observed a significant MDA level decrease in the cortex (39%, p <0.001), striatum (28%, p <0.001), hippocampus (21%, p <0.05) and thalamus (20%, p <0.05), together with a decreased OSI level in the thalamus (71%, p <0,001), cortex (70%, p <0.05), striatum (65%, p <0.001), and hippocampus (57%, p <0.05). In group III compared to group I was observed decrease in MDA level in the cortex (40%, p <0.001). Propofol inhibits oxidative stress in all the evaluated structures of the rat brain with Parkinson’s disease. There are significant differences in the response of brain tissues to administered propofol between rats with PD and healthy ones.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.